Skip to main content

Summary

for people ages 18 years and up (full criteria)
at San Francisco, California and other locations
study started
estimated completion:

Description

Summary

The purpose of this study is to identify mechanisms associated with acquired immune escape by comparing baseline and at-progression tissue samples from participants who derive clinical benefit from CPI treatment of metastatic cancer.

Official Title

A Multicenter Study to Explore the Mechanism of Acquired Immune Escape In Patients With Metastatic Cancer Progressing on Checkpoint Inhibitor Therapy

Keywords

Neoplasms Metastatic Cancer Neoplasm Metastasis

Eligibility

You can join if…

Open to people ages 18 years and up

  • Response assessment of complete response (CR), partial response (PR), long stable disease (SD) for >3 months with a cancer immunotherapy treatment for metastatic cancer either through a marketed CPI or through participation in a Roche/Genentech CPI clinical trial.
  • Availability of tumor biopsy material extracted and preserved by the investigating site.

You CAN'T join if...

• Participants taking CPI combination therapies with chemotherapy are not permitted.

Locations

  • UCSF Comp Canc Ctr not yet accepting patients
    San Francisco, California, 94115, United States
  • Washington University School of Medicine; Dept of Medicine/Div of Medical Oncology accepting new patients
    Saint Louis, Missouri, 63108, United States
  • Sarah Cannon Cancer Center not yet accepting patients
    Arrington, Tennessee, 37014, United States
  • Herbert Irving Comprehensive Cancer Center; Herbert Irving Pavillion accepting new patients
    New York, New York, 10032, United States
  • Dana-Farber Cancer Institute accepting new patients
    Boston, Massachusetts, 02215, United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Hoffmann-La Roche
ID
NCT03333655
Phase
Phase 4
Study Type
Interventional
Last Updated
April 2, 2018
I’m interested in this study!